Inhibition of the BGR-ABL tyrosine kinase for the treatment of chronic myeloid leukemia

被引：0
|
作者：
Coulombel, L [1 ]
机构：
[1] INSERM U474, F-75014 Paris, France
来源：
M S-MEDECINE SCIENCES | 2001年 / 17卷 / 8-9期
关键词：
D O I：
10.4267/10608/2038
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：952 / 953
页数：2
相关论文
共 50 条
  • [31] When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
    Pierre Laneuville
    Current Treatment Options in Oncology, 2018, 19
  • [32] When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
    Laneuville, Pierre
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (03)
  • [33] ASSESSMENT OF EFFICACY OF TYROSINE KINASE INHIBITORS IN TREATMENT OF CHRONIC MYELOID LEUKEMIA
    Yadrikhinskaya, V. N.
    Mulina, I. I.
    Sannikova, A. N.
    Palshina, A. M.
    Sleptsova, S. S.
    Aleksandrova, T. N.
    YAKUT MEDICAL JOURNAL, 2016, (04): : 30 - 33
  • [34] Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
    Baccarani, Michele
    Castagnetti, Fausto
    Gugliotta, Gabriele
    Palandri, Francesca
    Rosti, Gianantonio
    EXPERT REVIEW OF HEMATOLOGY, 2014, 7 (03) : 397 - 406
  • [35] Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
    Giles, F. J.
    O'Dwyer, M.
    Swords, R.
    LEUKEMIA, 2009, 23 (10) : 1698 - 1707
  • [36] Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia
    Radich, Jerald P.
    Mauro, Michael J.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (04) : 577 - +
  • [37] Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
    F J Giles
    M O'Dwyer
    R Swords
    Leukemia, 2009, 23 : 1698 - 1707
  • [38] Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia
    Jabbour, Elias J.
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (12) : 1433 - 1452
  • [39] Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia
    Haddad, Fadi
    Kantarjian, Hagop
    Issa, Ghayas C.
    Jabbour, Elias
    Sasaki, Koji
    LEUKEMIA & LYMPHOMA, 2022, 63 (07) : 1714 - 1717
  • [40] Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis
    Soverini, Simona
    Martinelli, Giovanni
    Rosti, Gianantonio
    Iacobucci, Ilaria
    Baccarani, Michele
    PHARMACOGENOMICS, 2012, 13 (11) : 1271 - 1284
12345